ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,266.95
-0.74%
US Tech 100
18,178.40
-1.14%
다우존스 지수
38,441.54
-1.06%
Bitcoin
67,917.06
0.49%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) 뉴스

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:GLUE
일자시간출처헤드라인심볼기업
2024/05/2120:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/1705:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/1705:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/1620:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/1605:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/1605:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/0920:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/0920:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/0920:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/05/0305:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/03/1420:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/03/1120:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/3121:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0821:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0821:15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0506:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0506:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0506:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0506:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0506:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/01/0321:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/11/2121:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/11/0921:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/11/0921:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/11/0800:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/10/2720:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/10/2706:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/10/2705:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/10/2705:30GlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2023/10/1720:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
 검색 관련기사 보기:NASDAQ:GLUE

최근 히스토리

NASDAQ
CAAZX
American Funds College 2...
NASDAQ
ZABDAX
Actis Africa Real Estate 3
COIN
PSYCHOUSD
Psycho
NASDAQ
FNDACX
Equity Allocation Etf Mo...
NASDAQ
ZAAWQX
Accel Xvi
LSE
55OP
Orig.ml.s4 31
USOTC
WEGZY
Weg (PK)
BMF
IR1Q21V21
KOSPI
610039
US Treasury Bond 30y ETN...
COIN
ANSUSD
COIN
SHAVEUR
NASDAQ
EMIF
iShares Emerging Markets...
USOTC
GTGED
G2 Energy (PK)
TG
AFZ
Africa Oil
NASDAQ
CNECX
Alger Concentrated Equit...
NASDAQ
FDBAQX
S&P International Divide...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유